Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00035295
NCT00035295
Completed
Phase 3

A Double-Blind, Multicenter, Placebo-and Active-Controlled Acute and Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder

Merck Sharp & Dohme LLC0 sites584 target enrollmentNovember 8, 2001
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMajor Depressive Disorder
DrugsMK0869, aprepitantComparator: placebo

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Major Depressive Disorder
Sponsor
Merck Sharp & Dohme LLC
Enrollment
584
Primary Endpoint
HAMD-17 total score at week 8. Tolerability.
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

A clinical study to determine the efficacy and safety of an Treatment of MK0869

in the treatment of depression.

Detailed Description

The duration of treatment is 8 weeks.

Registry
clinicaltrials.gov
Start Date
November 8, 2001
End Date
December 5, 2003
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

HAMD-17 total score at week 8. Tolerability.

Secondary Outcomes

  • CGI-I score at week 8, at least 50% reduction in the HAMD-17 total score, and Sheehan Disability Score at Week 8

Similar Trials

Completed
Phase 3
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)Major Depressive Disorder
NCT00048594Merck Sharp & Dohme LLC800
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)Major Depressive Disorder
NCT00035048Merck Sharp & Dohme LLC540
Completed
Phase 2
A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)Diabetes Mellitus, Type 2
NCT00631488Merck Sharp & Dohme LLC146
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)Major Depressive Disorder
NCT00035282Merck Sharp & Dohme LLC450
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)Major Depressive Disorder
NCT00034983Merck Sharp & Dohme LLC900